ADMINISTRATION OF MGLU2/3R AGONIST IN A MODEL OF CHRONIC CEREBRAL HYPOPERFUSION

JUAN TURATI; AMANDA NUNES SANTIAGO; LILA CARNIGLIA; JULIETA SABA; CARLA CARUSO; DANIELA DURAND; RÚBIA MARÍA WEFFOR DE OLIVEIRA; MERCEDES LASAGA

Mar del Plata

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2019

SAIC

Chronic cerebral hypoperfusion (CCH)resembles central changes in aging-related vascular dementiasand Alzheimer ́s disease (AD). Our group has demonstrated, invitro, that astroglial subtype 3 metabotropic glutamate receptors(mGlu3R) present protective actions against neurotoxic agentsincluding Aß. However, contradictory results were reported whenmGlu3R ligands were administered in vivo. We examined theeffect of the mGlu2/3R agonist, LY376298 (LY) 1 mg/kg i.p., inmiddle aged rats with CCH. The effect of mGlu2/3R agonist inneuron cell death and glial activation of the hippocampus weredetermined by immunohistochemistry. Moreover, the expressionof GRM2, GRM3 (mGlu2/3R genes), GFAP and BDNF was studiedby RT-qPCR technique. NeuN expression presents a decreased inCCH animals (p